DIO-902 + metformin + atorvastatin

This is a **triple combination therapy** consisting of DIO-902 (levdexketoconazole), metformin, and atorvastatin. - **DIO-902** is the (2S,4R)-enantiomer of ketoconazole, developed as a selective cortisol synthesis inhibitor (primarily targeting 11β-hydroxylase) to lower cortisol levels, improve glycemic control, and reduce cholesterol in patients with type 2 diabetes mellitus[1][2][3][5][7]. - **Metformin** is a first-line oral antihyperglycemic agent that decreases hepatic glucose production and increases insulin sensitivity. - **Atorvastatin** is a statin class lipid-lowering drug that inhibits HMG-CoA reductase, reducing cholesterol synthesis and lowering LDL cholesterol. This combination aims for synergistic control of blood glucose (metformin and DIO-902 via different mechanisms) and lipid abnormalities (atorvastatin and DIO-902 both lower cholesterol but through complementary pathways), mainly in patients with **type 2 diabetes and dyslipidemia**. DIO-902 additionally may reduce cardiovascular risk markers such as C-reactive protein[1][3][4][5][7].

Other names

levdexketoconazole + metformin + atorvastatin